Pharmacological cyclin dependent kinase inhibitors： Implications for colorectal cancer

Colorectal cancer accounts for a significant proportionof cancer deaths worldwide. The need to develop morechemotherapeutic agents to combat this disease iscritical. Cyclin dependent kinases （CDKs）, along withits binding partner cyclins, serve to control the growthof cells through the cell cycle. A new class of drugs,termed CDK inhibitors, has been studied in preclinicaland now clinical trials. These inhibitors are believed toact as an anti-cancer drug by blocking CDKs to blockthe uncontrolled cellular proliferation that is hallmarkof cancers like colorectal cancer. CDK article providesoverview of the emerging drug class of CDK inhibitorsand provides a list of ones that are currently in clinicaltrials.